Download PDF
Thromb Haemost 1993; 69(04): 321-327
DOI: 10.1055/s-0038-1651605
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Influence of Acute Myocardial Infarction and rt-PA Therapy on Circulating Fibrinogen

E Seifried
1   The Medizinische Klinik und Poliklinik, Universität Ulm, Germany
,
M Oethinger
1   The Medizinische Klinik und Poliklinik, Universität Ulm, Germany
,
P Tanswell
2   The Thomae GmbH, Biberach, Germany
,
E Hoegee-de Nobel
3   The Gaubius Institute TNO, Leiden, The Netherlands
,
W Nieuwenhuizen
3   The Gaubius Institute TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 26 June 1992

Accepted after revision 17 December 1992

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In 12 patients treated with 100 mg rt-PA/3 h for acute myocardial infarction (AMI), serial fibrinogen levels were measured with the Clauss clotting rate assay (“functional fibrinogen”) and with a new enzyme immunoassay for immunologically intact fibrinogen (“intact fibrinogen”). Levels of functional and “intact fibrinogen” were strikingly different: functional levels were higher at baseline; showed a more pronounced breakdown during rt-PA therapy; and a rebound phenomenon which was not seen for “intact fibrinogen”. The ratio of functional to “intact fibrinogen” was calculated for each individual patient and each time point. The mean ratio (n = 12) was 1.6 at baseline, 1.0 at 90 min, and increased markedly between 8 and 24 h to a maximum of 2.1 (p <0.01), indicating that functionality of circulating fibrinogen changes during AMI and subsequent thrombolytic therapy. The increased ratio of functional to “intact fibrinogen” seems to reflect a more functional fibrinogen at baseline and following rt-PA infusion. This is in keeping with data that the relative amount of fast clotting “intact HMW fibrinogen” of total fibrinogen is increased in initial phase of AMI. The data suggest that about 20% of HMW fibrinogen are converted to partly degraded fibrinogen during rt-PA infusion. The rebound phenomenon exhibited by functional fibrinogen may result from newly synthesized fibrinogen with a high proportion of HMW fibrinogen with its known higher degree of phosphorylation. Fibrinogen- and fibrin degradation products were within normal range at baseline. Upon infusion of the thrombolytic agent, maximum median levels of 5.88 μg/ml and 5.28 μg/ml, respectively, were measured at 90 min. Maximum plasma fibrinogen degradation products represented only 4% of lost “intact fibrinogen”, but they correlatedstrongly and linearly with the extent of “intact fibrinogen” degradation (r = 0.82, p <0.01). In contrast, no correlation was seen between breakdown of “intact fibrinogen” and corresponding levels of fibrin degradation products. We conclude from our data that the ratio of functional to immunologically “intact fibrinogen” may serve as an important index for functionality of fibrinogen and select patients at high risk for early reocclusion. Only a small proportion of degraded functional and “intact fibrinogen”, respectively, is recovered as fibrinogen degradation products. There seems to be a strong correlation between the degree of elevation of fibrinogen degradation products and the intensity of the systemic lytic state, i.e. fibrinogen degradation.

 

  • References

  • 1 Marder VJ, Sherry S. Thrombolytic therapy: current status (First of two parts). N Engl J Med 1988; 318 23: 1512-1520
    PubMedGoogle Scholar
  • 2 Marder VJ, Sherry S. Thrombolytic therapy: current status (Second of two parts). N Engl J Med 1988; 318 24: 1585-1595
    PubMedGoogle Scholar
  • 3 Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 581-588
    CrossrefPubMedGoogle Scholar
  • 4 Lane DA, Rampling MW, Kakkar VV. A comparison of the sulphite and thrombin methods for measuring fibrinogen concentration of plasma from patients undergoing thrombolytic therapy. Clin Chim Acta 1976; 71: 15-19
    CrossrefPubMedGoogle Scholar
  • 5 Jespersen J, Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol 1982; 67: 2-7
    CrossrefPubMedGoogle Scholar
  • 6 Hoffmann JJML, Verhappen MAL. Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. Clin Chem 1988; 34: 2135-2140
    PubMedGoogle Scholar
  • 7 Koppert PW, Kuipers W, Hoegee-de Nobel E, Brommer EJP, Koopman J, Nieuwenhuizen W. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma. Thromb Haemostas 1987; 57: 25-28
    PubMedGoogle Scholar
  • 8 Koppert PW, Hoegee-de Nobel E, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemostas 1988; 59: 310-315
    PubMedGoogle Scholar
  • 9 Nieuwenhuizen W. New strategies in the determination of fibrin and fibrino(gen) derivatives by monoclonal antibodies. Blut 1988; 57: 285-291
    CrossrefPubMedGoogle Scholar
  • 10 Elms MJ, Bunce JH, Bundesen PG, Rylatt DB, Webber A, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - An immunoassay using monoclonal antibodies. Thromb HaeilUlstas 1983; 50: 591-594
    PubMedGoogle Scholar
  • 11 Whitaker AN, Elms MJ, Masci PP. Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-887
    CrossrefPubMedGoogle Scholar
  • 12 Nossel HL, Younger LR, Wilner GD, Procupez T, Canfield RE, Butler VP. Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci 1971; 68: 2350-2353
    CrossrefPubMedGoogle Scholar
  • 13 Kudryk B, Rohaza A, Ahadi M, Chin J, Wiebe ME. A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983; 20: 1191-2000
    CrossrefPubMedGoogle Scholar
  • 14 Weitz JI, Koehn JA, Canfield RE, Landman SL, Friedman R. Development of a radioimmunoassay for the fibrinogen-derived peptide Bβl-42. Blood 1986; 67: 1014-1022
    PubMedGoogle Scholar
  • 15 Eisenberg PR, Sherman L, Rich M, Schwartz D, Schetman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986; 7: 1255-1262
    CrossrefPubMedGoogle Scholar
  • 16 Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 980-989
    CrossrefPubMedGoogle Scholar
  • 17 Seifried E, Tanswell P, Ellbrück D, Haerer W, Schmidt A. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen ativator in patients with acute myocardial infarction. Thromb Haemostas 1989; 61: 497-501
    PubMedGoogle Scholar
  • 18 Seifried E, Rijken DC, Hoegee E, Tanswell P, Kluft C, Nieuwenhuizen W. Fibrin degradation products - FbD’s - appear in blood of healthy volunteers upon infusion of recombinant tissue type plasminogen activator (rt-PA). In: Fibrinogen 2. Biochemistry, Physiology and Clinical Relevance. Lowe GDO. (ed). Amsterdam: Elsevier Science Publishers BV; (Biomedical Division) 1987: 289-292
    Google Scholar
  • 19 Seifried E, Tanswell P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet II 1987; 8554: 333-334
    PubMedGoogle Scholar
  • 20 Tanswell P, Seifried E, Su CAPF, Feuerer W, Rijken DC. Pharmacokinetics and systemic effects of tissue-type activator in normal subjects. Clin Pharm Therap 1989; 460: 155-162
    PubMedGoogle Scholar
  • 21 Hoegee-de Nobel E, Voskuilen M, Briët E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quanitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemostas 1988; 60: 415-418
    PubMedGoogle Scholar
  • 22 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 23 Koppert PW, Huijsmans CMG, Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-containing fragments and not reacting with free fibrinopeptide A. Blood 1985; 3: 503-507
    PubMedGoogle Scholar
  • 24 Stötzer KE, Amiral J, Spanuth E. Neue Methoden zur spezifischen Bestimmung von Fibrinspaltprodukten (D-Dimere). Lab Med 1988; 12: 51-59
    PubMedGoogle Scholar
  • 25 Haverkate F, Koopman J, Koppert P, Nieuwenhiuzen W. Determination of fibrin(ogen) degradation products (FDP) in plasma, using a monoclonal antibody. Scand J Clin Lab Invest 1985; 45 (Suppl. 178) 153
    PubMedGoogle Scholar
  • 26 Koopman J, Haverkate F, Koppert PW, Nieuwenhuizen W, Brommer EJP, van der Werf WGC. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987; 109: 75-84
    PubMedGoogle Scholar
  • 27 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
    CrossrefPubMedGoogle Scholar
  • 28 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 5: 1482-1487
    PubMedGoogle Scholar
  • 29 Seifried E, Tanswell P. Comparison of specific antibody, D-Phe-Pro-Arg-CH2C1 and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemostas 1987; 58 (03) 921-926
    PubMedGoogle Scholar
  • 30 Oethinger MD, Seifried E. In vitro effects of urokinase - prevention by different inhibitors. Thromb Haemostas 1990; 64: 402-406
    PubMedGoogle Scholar
  • 31 Holm B, Godal HC. Quantitation of the three normally occurring plasma fibrinogen in health and during socalled “acute phase” by SDS electrophoresis of fibrin obtained form EDTA-plasma. Thromb Res 1984; 35: 279-290
    CrossrefPubMedGoogle Scholar
  • 32 Koppert PW, Koopman J, Haverkate F, Nieuwenhuizen W. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising Bβ 54-118) in degradation products of fibrin and of fibrinogen. Blood 1986; 68: 437-441
    PubMedGoogle Scholar
  • 33 Merskey C, Lalezary P, Johnsons AJ. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-875
    CrossrefPubMedGoogle Scholar
  • 34 Hoffmann JJML, Vijgen M, Nieuwenhuizen W. Comparison of the specificity of four fibrinogen assays during thrombolytic therapy. Fibrinolysis 1990; 4 (Suppl. 02) 121-123
    PubMedGoogle Scholar
  • 35 Holm B, Nilsen DWT, Kierulf R, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-176
    CrossrefPubMedGoogle Scholar
  • 36 Vila V, Regafion E, Aznar J, Lacueva V, Ruano M, Laiz B. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res 1990; 57: 783-794
    CrossrefPubMedGoogle Scholar
  • 37 Regañon E, Vila Virtudes, Aznar J, Laiz B. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation. Clin Chim Acta 1989; 184: 7-18
    CrossrefPubMedGoogle Scholar
  • 38 Mirshahi M, Soria J, Soria C, Samama M, Caen JP. Degradation of fibrinogen by tissue plasminogen activator. Consequences for fibrin polymerization. Thromb Res 1990; (Suppl. 10) 21-26
    PubMedGoogle Scholar
  • 39 Seydewitz HH, Kaiser C, Rothweiler H, Witt I. The location of a second in vivo phosphorylation site in the Aα-chain of human fibrinogen. Thromb Res 1984; 33: 487-498
    CrossrefPubMedGoogle Scholar
  • 40 Leeksma OC. Fibrinogen, fibrinopeptide A, platelets and endothelial cells. Thesis. Amsterdam: 1985
    PubMedGoogle Scholar
  • 41 Seifried E, Tanswell P. Current developments in thrombolytic therapy using novel plasminogen activators. Arzneimittelforsch/Drug Res 1989; 39: 1474-1482
    PubMedGoogle Scholar
  • 42 Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, Brower RW, de Bono DP, Huhmann W, Lubsen J, Meyer J, Rutsch W, Schmidt W, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; I: 842-847
    PubMedGoogle Scholar
  • 43 Francis CW, Connaghan DG, Marder VJ. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986; 74: 1027-1036
    CrossrefPubMedGoogle Scholar